These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 12956767
1. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A. Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767 [Abstract] [Full Text] [Related]
2. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients. Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA. Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805 [Abstract] [Full Text] [Related]
3. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease]. Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146 [Abstract] [Full Text] [Related]
4. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404 [Abstract] [Full Text] [Related]
5. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis]. González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S. Med Intensiva; 2010 Nov 01; 34(8):513-22. PubMed ID: 20627371 [Abstract] [Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S. Endocr J; 2007 Aug 01; 54(4):593-9. PubMed ID: 17690487 [Abstract] [Full Text] [Related]
7. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Thromb Haemost; 2003 Jul 01; 90(1):92-100. PubMed ID: 12876631 [Abstract] [Full Text] [Related]
8. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T. Haematologica; 2009 Jun 01; 94(6):811-8. PubMed ID: 19377074 [Abstract] [Full Text] [Related]
9. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S. J Endocrinol Invest; 2007 Nov 01; 30(10):810-9. PubMed ID: 18075282 [Abstract] [Full Text] [Related]
10. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer. Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W. Blood Coagul Fibrinolysis; 2013 Oct 01; 24(7):698-703. PubMed ID: 23624357 [Abstract] [Full Text] [Related]
11. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Segev A, Hegele RA, Lau HK, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Thromb Res; 2004 Oct 01; 114(2):137-41. PubMed ID: 15306156 [Abstract] [Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity. Hamdy M, Shaheen IA, Khallaf M, Selim YMM. Pediatr Blood Cancer; 2024 Jun 01; 71(6):e30959. PubMed ID: 38520679 [Abstract] [Full Text] [Related]
13. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease. Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V. Thromb Res; 2018 Nov 01; 171():171-176. PubMed ID: 30321704 [Abstract] [Full Text] [Related]
14. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790 [Abstract] [Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism. Ermantas N, Guldiken S, Demir M, Tugrul A. Clin Appl Thromb Hemost; 2010 Oct 08; 16(5):568-73. PubMed ID: 19959491 [Abstract] [Full Text] [Related]
16. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study. Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A. Meta Gene; 2015 Jun 08; 4():73-84. PubMed ID: 25893174 [Abstract] [Full Text] [Related]
17. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H. J Endocrinol Invest; 2009 Feb 08; 32(2):169-74. PubMed ID: 19411818 [Abstract] [Full Text] [Related]
18. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases. Naderi M, Alizadeh S, Kazemi A, Tabibian S, Zaker F, Bamedi T, Kashani Khatib Z, Dorgalaleh A. Hematology; 2015 Mar 08; 20(2):112-8. PubMed ID: 25001244 [Abstract] [Full Text] [Related]
19. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J. J Thromb Haemost; 2007 Sep 08; 5(9):1862-8. PubMed ID: 17723126 [Abstract] [Full Text] [Related]
20. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Chudý P, Kotuličová D, Staško J, Kubisz P. Blood Coagul Fibrinolysis; 2011 Sep 08; 22(6):493-8. PubMed ID: 21519232 [Abstract] [Full Text] [Related] Page: [Next] [New Search]